ClinicalTrials.gg
CompletedNCT07738783USDLO-MPSUpdated Nov 4, 2026

Ultrasound-Guided Dry Needling, Lidocaine Injection, and Oxygen-Ozone Injection for Myofascial Pain Syndrome

An interventional study of Dry Needling and Lidocaine Injection (1%, 2 mL) in Myofascial Pain Syndrome (Upper Trapezius), sponsored by Derince Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Derince Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2025, registered Jul 2026).
Updated Nov 4, 2026Primary completion movedStudy completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Myofascial Pain Syndromes with a site in Turkey — 12 open to participants now, 12 under way, none of them phase 3. Myofascial Pain Syndromes · Turkey.

Enrollment
12th of 67
81 · median 60
Started
2025
with 7 others
No phase
62 of 81
8 open now
Registered
74th of 81
by date

Among the 81 studies in Myofascial Pain Syndromes with a site in Turkey, this one is the 12th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2025, is one of 62 with no phase, and was the 74th registered.

Myofascial Pain Syndromes

340 studies on the registry are indexed under Myofascial Pain Syndromes; 67 are open to participants now.

Browse Myofascial Pain Syndromes studies →

Open to participants now

12 of the 81 studies in Myofascial Pain Syndromes with a site in Turkey are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 35 Myofascial Pain Syndromes studies recruiting now, 6 (17%) set no upper age limit and 26 (74%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Myofascial Pain Syndromes with a site in Turkey, or all of them as a file.
02

Study summary

Prospective, assessor-blinded, three-arm randomized controlled trial comparing ultrasound-guided dry needling, lidocaine injection, and oxygen-ozone injection in patients with myofascial pain syndrome (MPS) of the upper trapezius muscle. A total of 81 participants were randomized (27 per arm) to receive the assigned intervention once weekly for 3 sessions plus a standardized home exercise program; 76 participants completed follow-up and were analyzed (dry needling, n=25; lidocaine, n=25; oxygen-ozone, n=26). Clinical (pain, function, sleep, quality of life) and ultrasonographic (tissue imaging, blood flow waveform) outcomes were assessed at baseline, Week 4, and Week 12.

Read the detailed description

Design: Prospective, three-arm, parallel-group randomized controlled trial with blinded outcome assessment and statistical analysis, conducted between June 2025 and August 2026.

Randomization: Computer-generated block randomization (1:1:1; block size = 6, with a final block of 3); allocation concealment with sequentially numbered, sealed, opaque envelopes. Of 110 patients screened, 81 were randomized (27 per group); 5 participants discontinued before completing the three treatment sessions, and 76 completed follow-up and were analyzed.

Blinding: Clinical and ultrasonographic outcomes were assessed by a separate physiatrist (10 years of experience in musculoskeletal ultrasonography) who was not involved in the interventions and was blinded to group allocation. Statistical analyses were performed on a coded dataset by an investigator blinded to group allocation. Blinding of participants and the interventionist was not feasible because of the nature of the interventions.

Interventions: All procedures were performed under real-time ultrasound guidance (GE LOGIQ P5, 4-15 MHz linear probe) and aseptic conditions by a single physiatrist and algologist with 15 years of experience in musculoskeletal ultrasonography, using a 40-mm, 27-gauge needle in all groups. In each patient, a single active trigger point (the most painful one, on the more symptomatic side) was treated unilaterally once weekly for three sessions. All participants performed a standardized daily home exercise program; analgesics, nonsteroidal anti-inflammatory drugs, and other treatments were not permitted during the study.

03

Conditions studied

  • Myofascial Pain Syndrome (Upper Trapezius)

Keywords

  • Myofascial Pain Syndrome
  • Dry Needling
  • Lidocaine Injection
  • Ozone Therapy
  • Ultrasonography
  • Trigger Points
  • Neck Pain
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Neck pain of at least 3 months' duration
  • Diagnosis of myofascial pain syndrome (MPS) according to the Simons and Travell criteria
  • At least one active myofascial trigger point in the upper trapezius muscle, defined by the concurrent presence of all of the following: (1) a palpable taut band, (2) a hypersensitive tender spot within the taut band, and (3) reproduction of the patient's familiar pain on digital compression. A taut band alone was not sufficient for inclusion.

Exclusion criteria

Exclusion Criteria:

  • Cervical radiculopathy or myelopathy
  • Advanced degenerative cervical spine disease
  • History of neck trauma or surgery within the previous year
  • Prior injection into the trapezius muscle within the last 3 months
  • Relevant systemic conditions, including fibromyalgia, rheumatoid arthritis, polyneuropathy, malignant hypertension, coagulopathy, or severe thrombocytopenia ( count \<50,000/µL)
  • Anticoagulant therapy
  • to oxygen-ozone injection: glucose-6-phosphate dehydrogenase (G6PD) deficiency or uncontrolled hyperthyroidism (including Graves' disease)
  • Known allergy to local anesthetics
  • Cognitive impairment
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    Dry Needling

    Participants received ultrasound-guided dry needling of a single active upper trapezius trigger point using a 40-mm, 27-gauge needle with the fast-in, fast-out multidirectional technique to elicit local twitch responses, without injection of any substance. Once weekly for three sessions, combined with a standardized home exercise program.

    Device: Dry Needling

  • Active comparator
    Lidocaine Injection

    Participants received ultrasound-guided injection of 2 mL of 1% lidocaine into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle; local twitch responses were intentionally elicited with the same multidirectional technique as in the dry needling group, and the injectate was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.

    Drug: Lidocaine Injection (1%, 2 mL)

  • Active comparator
    Oxygen-Ozone Injection

    Participants received ultrasound-guided injection of 5 mL of an oxygen-ozone mixture (ozone concentration 10 μg/mL) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle; local twitch responses were intentionally elicited with the same multidirectional technique as in the dry needling group, and the mixture was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.

    Drug: Oxygen-Ozone Injection (10 μg/mL, 5 mL)

Interventions

  • DeviceDry Needling

    Ultrasound-guided dry needling of a single active upper trapezius trigger point using a 40-mm, 27-gauge needle with the fast-in, fast-out multidirectional technique (approximately 20 insertions over approximately 30 seconds) to elicit local twitch responses, continued until no further local twitch responses could be elicited. No substance was injected. Once weekly for three sessions, combined with a standardized home exercise program.

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ultrasound-guided injection of 2 mL of 1% lidocaine (1 mL of 2% lidocaine hydrochloride diluted with 1 mL of 0.9% sodium chloride immediately before injection) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle. Local twitch responses were intentionally elicited with the same multidirectional technique used in the dry needling group, and the injectate was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.

  • DrugOxygen-Ozone Injection (10 μg/mL, 5 mL)

    Ultrasound-guided injection of 5 mL of an oxygen-ozone mixture (ozone concentration 10 μg/mL, produced from medical-grade oxygen with a calibrated medical ozone generator and injected within 30 seconds of withdrawal) into a single active upper trapezius trigger point using a 40-mm, 27-gauge needle. Local twitch responses were intentionally elicited with the same multidirectional technique used in the dry needling group, and the mixture was distributed in a fan-shaped manner within the trigger point. Once weekly for three sessions, combined with a standardized home exercise program.

06

What researchers measure

Primary outcomes

  1. Pain Intensity (Visual Analog Scale, VAS)

    "Pain intensity was assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain)."

    Time frame: Baseline, Week 4, and Week 12

Secondary outcomes

  1. Neck Disability Index (NDI)

    "Functional status was evaluated using the Neck Disability Index, a 10-item questionnaire with scores ranging from 0 to 50, where higher scores indicate greater disability."

    Time frame: Baseline, Week 4, and Week 12

  2. Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality assessed with the Pittsburgh Sleep Quality Index (PSQI). Global score range 0-21; higher scores indicate poorer sleep quality (scores \>5 indicate poor sleep).

    Time frame: Baseline, Week 4, and Week 12

  3. Short Form-36 (SF-36)

    Health-related quality of life assessed with the Short Form-36 Health Survey (SF-36), reported for its eight domains (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Each domain is scored 0-100; higher scores indicate better health status.

    Time frame: Baseline, Week 4, and Week 12

  4. Tissue Imaging Score (TIS)

    "Ultrasonographic tissue imaging score assessed via grayscale ultrasonography to evaluate echogenicity and structural characteristics of the trigger point muscle segment; scored 0 (normal homogeneous structure), 1 (single focal hypoechoic area), or 2 (multiple hypoechoic nodules)."

    Time frame: Baseline, Week 4, and Week 12

  5. Blood Flow Waveform Score (BFS)

    Ordinal Doppler blood flow waveform score (BFS, 0-2) of the small intramuscular arterial branch closest to the trigger point site, based on pulsed-wave Doppler and the resistive index (RI = \[peak systolic velocity - end-diastolic velocity\] / peak systolic velocity): 0 = normal resting muscle arterial flow without diastolic flow (RI = 1); 1 = increased diastolic flow indicating reduced vascular bed resistance (RI \< 1); 2 = high-resistance waveform with retrograde (negative) diastolic flow (RI \> 1). Higher scores indicate a more abnormal waveform.

    Time frame: Baseline, Week 4, and Week 12

07

Study locations

1 site
  • Derince Training and Research Hospital, University of Health Sciences
    Kocaeli, Derince 41300, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Aug 2026, 14 months.

Of 203 non-industry interventional studies with no phase under Myofascial Pain Syndromes, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 14 months is above that.

Counting every sponsor, half of 205 studies reached it within 5 months; a quarter within 2 and three quarters within 13.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion May 2026 → Aug 2026 and completion May 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartActual
Jun 17, 2025
Primary completionActual
Aug 29, 2026was May 2026
CompletionActual
Aug 29, 2026was May 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 22, 2026→Aug 29, 2026
Nov 4, 2026
Study completion
May 22, 2026→Aug 29, 2026
Nov 4, 2026
Enrollment
76→81
Nov 4, 2026
Eligibility
1 inclusion criterion added, 2 removed; 1 exclusion criterion edited, 3 added
What changed in the criteria
Inclusion criteria
  • RemovedAt least one active trigger point and/or palpable taut band within the upper trapezius muscle
  • RemovedReproduction of typical pain upon digital compression of the trigger point
  • AddedAt least one active myofascial trigger point in the upper trapezius muscle, defined by the concurrent presence of all of the following: (1) a palpable taut band, (2) a hypersensitive tender spot within the taut band, and (3) reproduction of the patient's familiar pain on digital compression. A taut band alone was not sufficient for inclusion.
Exclusion criteria
  • EditedSystemicRelevant systemic conditions, including fibromyalgia, rheumatoid arthritis, polyneuropathy, coagulopathy, malignant hypertension, Graves' diseasecoagulopathy, or severe thrombocytopenia (platelet count <50,000/µL)
  • AddedAnticoagulant therapy
  • AddedContraindications to oxygen-ozone injection: glucose-6-phosphate dehydrogenase (G6PD) deficiency or uncontrolled hyperthyroidism (including Graves' disease)
  • AddedKnown allergy to local anesthetics
Nov 4, 2026
Interventions
Added Device: Dry Needling; removed Device: Dru Needling
Nov 4, 2026
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionBlood Flow Waveform Score (BFS): how it is measured was reworded
  • DescriptionPittsburgh Sleep Quality Index (PSQI): how it is measured was reworded
  • DescriptionShort Form-36 (SF-36): how it is measured was reworded
Nov 4, 2026
Title
Ultrasound-Guided Dry Needling, Lidocaine Injection, and Oxygen-Ozone TherapyInjection for Myofascial Pain Syndrome
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion May 22, 2026→Aug 29, 2026
    Study completion May 22, 2026→Aug 29, 2026
    Enrollment 76→81
    Eligibility 1 inclusion criterion added, 2 removed; 1 exclusion criterion edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • RemovedAt least one active trigger point and/or palpable taut band within the upper trapezius muscle
    • RemovedReproduction of typical pain upon digital compression of the trigger point
    • AddedAt least one active myofascial trigger point in the upper trapezius muscle, defined by the concurrent presence of all of the following: (1) a palpable taut band, (2) a hypersensitive tender spot within the taut band, and (3) reproduction of the patient's familiar pain on digital compression. A taut band alone was not sufficient for inclusion.
    Exclusion criteria
    • EditedSystemicRelevant systemic conditions, including fibromyalgia, rheumatoid arthritis, polyneuropathy, coagulopathy, malignant hypertension, Graves' diseasecoagulopathy, or severe thrombocytopenia (platelet count <50,000/µL)
    • AddedAnticoagulant therapy
    • AddedContraindications to oxygen-ozone injection: glucose-6-phosphate dehydrogenase (G6PD) deficiency or uncontrolled hyperthyroidism (including Graves' disease)
    • AddedKnown allergy to local anesthetics
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionBlood Flow Waveform Score (BFS): how it is measured was reworded
    • DescriptionPittsburgh Sleep Quality Index (PSQI): how it is measured was reworded
    • DescriptionShort Form-36 (SF-36): how it is measured was reworded
    Interventions Added Device: Dry Needling; removed Device: Dru Needling
    Title Ultrasound-Guided Dry Needling, Lidocaine Injection, and Oxygen-Ozone TherapyInjection for Myofascial Pain Syndrome
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07738783
Lead sponsor
Derince Training and Research Hospital
Collaborators
Sivas Numune Hospital, Dokuz Eylul University
Responsible party
İlhan Celil Özbek (MD, Derince Training and Research Hospital) — Principal investigator
First posted
Jul 31, 2026
Start date
Jun 17, 2025
Primary completion
Aug 29, 2026
Completion
Aug 29, 2026
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion